Clinical Trials Browser

Topotecan × Clear all

NCT06172296 2026-05-27

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Phase 3 Recruiting

Neuroblastoma, Ganglioneuroblastoma

NCT06459180 2026-05-27

TroFuse-020

Phase 3 Active not recruiting

Uterine Cervical Neoplasms

NCT06619236 2026-05-27

RAINFOL-02

Phase 3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07099898 2026-05-27

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

Phase 3 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07213804 2026-05-27

FRAmework-01

Phase 3 Recruiting

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT07286266 2026-05-27

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Phase 3 Not yet recruiting

Ovarian Neoplasms

NCT06612151 2026-05-26

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

Phase 3 Active not recruiting

Small Cell Lung Carcinoma

NCT07214779 2026-05-26

MAESTRA 2

Phase 3 Recruiting

Ovarian Neoplasms

NCT07321912 2026-05-26

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Phase 2 Recruiting

Sarcoma, Ewing, Osteosarcoma

NCT05800587 2026-05-22

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT06161025 2026-05-22

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2/3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06616532 2026-05-22

PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

Phase 3 Active not recruiting

SCLC

NCT07604766 2026-05-22

RAINFOL-02

Phase 3 Not yet recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06801834 2026-05-20

EVOKE-SCLC-04

Phase 3 Recruiting

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT00602667 2026-05-19

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

Phase 2 Active not recruiting

293 enrolled 89 charts

Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Rhabdoid Tumor

NCT04514497 2026-05-19

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Phase 1 Active not recruiting

29 enrolled 25 charts

EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT07194044 2026-05-15

METTSEO

Phase 1 Recruiting

Sarcoma, Ewing

NCT06840886 2026-05-14

A Study of PHST001 in Advanced Solid Tumors

Phase 1 Recruiting

CNSGastrointestinalGynecologic

Ovarian Neoplasms, Central Nervous System Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05153239 2026-05-13

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

Phase 3 Completed

Small Cell Lung Carcinoma

NCT05353439 2026-05-13

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

Phase 1 Active not recruiting

Small Cell Lung Carcinoma

NCT02308527 2026-05-12

BEACON

Phase 2 Completed

Neuroblastoma

NCT02354547 2026-05-08

A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors

Phase 1 Suspended

Neoplasms

NCT04322318 2026-05-05

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Phase 2 Recruiting

Wilms Tumor

NCT06647953 2026-05-05

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Phase 3 Recruiting

Pleuropulmonary blastoma

NCT05613088 2026-04-30

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

106 enrolled 23 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01012817 2026-04-29

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Phase 1/2 Active not recruiting

88 enrolled 23 charts

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT02502266 2026-04-29

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Phase 2/3 Active not recruiting

582 enrolled 21 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03154996 2026-04-22

Chronic Convection Enhanced Delivery of Topotecan

Phase 1 Completed

Glioma, Recurrence

NCT05101551 2026-04-22

PARPAML

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07545460 2026-04-22

A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Phase 3 Not yet recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT04106219 2026-04-21

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Phase 1 Active not recruiting

Epilepsy, Neuroblastoma

NCT06828354 2026-04-20

A Study of SHR-A1811 in Subjects With Ovarian Cancer

Phase 3 Recruiting

Ovarian Neoplasms

NCT06994195 2026-04-20

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

Phase 3 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06449209 2026-04-17

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

Phase 2 Active not recruiting

Small Cell Lung Carcinoma

NCT06500026 2026-04-17

A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)

Phase 3 Active not recruiting

Small Cell Lung Carcinoma

NCT01857934 2026-04-16

Therapy for Children With Advanced Stage Neuroblastoma

Phase 2 Completed

153 enrolled 12 charts

Neuroblastoma

NCT06666712 2026-04-15

TPT CED rHGG

Phase 1 Recruiting

Brain Neoplasms, Glioma, Lymphoma, Follicular

NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

Phase 1/2 Not yet recruiting

Neuroblastoma, Ganglioneuroblastoma

NCT03289910 2026-04-13

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Phase 2 Active not recruiting

25 enrolled 15 charts

MyeloidOther hematologic neoplasm

Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03786783 2026-04-13

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Phase 2 Active not recruiting

42 enrolled 12 charts

Ganglioneuroblastoma

NCT03896503 2026-04-13

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Phase 2 Active not recruiting

104 enrolled 22 charts

Small Cell Lung Carcinoma

NCT04739800 2026-04-13

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Phase 2 Active not recruiting

120 enrolled 19 charts

GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT07418749 2026-04-06

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

Phase 3 Recruiting

Uterine Cervical Neoplasms

NCT05521984 2026-04-02

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Phase 1 Recruiting

Other solid neoplasm

Pediatric Brain Tumor

NCT05990738 2026-03-31

DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy

Phase 1 Active not recruiting

Small Cell Lung Carcinoma

NCT06930755 2026-03-31

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

Phase 1 Recruiting

Ovarian Neoplasms

NCT02298348 2026-03-23

N2013-02

Phase 1 Active not recruiting

Neuroblastoma, Recurrence

NCT02114229 2026-03-17

SJATRT

Phase 2 Active not recruiting

Rhabdoid Tumor

NCT06203210 2026-03-02

IDeate-Lung02

Phase 3 Recruiting

Small Cell Lung Carcinoma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Phase 3 Recruiting

Neuroblastoma, Ganglioneuroblastoma